linjc16/ctgov huggingface dataset:
Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors

Study Overview
=================
Brief Summary
-----------------
Only few reports exist on long-term survival after minimally invasive liver surgery (MILS for colorectal liver metastases. No data are available assessing prognostic factors in the era of current modern treatment strategies. The aim of the current study is to analyze the long-term oncologic outcome after MILS for metastases from colorectal cancer and determine prognostic indicators.

Conditions
-----------------
Long-term Oncologic Outcome of MILS in Patients With CRLM and Prognostic Indicators

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with CRLM Surgery: resection and/or ablation preoperative chemotherapy and/or biological agents are allowed postoperative chemotherapy and/or biological agents are allowed simultaneous colorectal resection is allowed Exclusion Criteria: primary liver cancer benign liver tumors pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CRLM<br>patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognostic variables |  | 5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver metastases, colorectal cancer, surgery, prognosis
Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy

Study Overview
=================
Brief Summary
-----------------
This study is designed to collect tissue samples that may aid in the treatment and learning about various oncology diagnosis.

Detailed Description
-----------------
The purpose of this study is to provide a mechanism to obtain tissue specimens to be used for experimental studies before the exact histologic diagnosis is known.

Official Title
-----------------
Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy

Conditions
-----------------
Lymphoma, Hodgkin Disease

Intervention / Treatment
-----------------
* Procedure: tumor tissue aspiration
* Procedure: phlebotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: tumor tissue aspiration|nan|
|Procedure: phlebotomy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Further analysis |  | at collection time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphoma, Hodgkin Disease
Corneal Crosslinking in Keratoconus and Corneal Ectasia

Study Overview
=================
Brief Summary
-----------------
Prospective, randomized, single site to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes progressive keratoconus or corneal ectasia.

Detailed Description
-----------------
After epithelial surface removal riboflavin drops are applied until there is saturation of the cornea.Then the UVA light is turned on to active the crosslinking process while drops are continued for the 30 minute of lamp use to replenish the riboflavin.

Official Title
-----------------
Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia

Conditions
-----------------
Progressive Keratoconus, Corneal Ectasia

Intervention / Treatment
-----------------
* Drug: Riboflavin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of keratoconus with documented progression over the previous 12 months. Diagnosis of corneal ectasia Must be able to complete all study visits. Exclusion Criteria: Prior corneal surgery in keratoconus group Corneal scarring Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Sham treatment<br>Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit. | Drug: Placebo<br>* Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.<br>|
| Active Comparator: Treatment Arm<br>After randomization, the active arm will have the collagen crosslinking intervention. | Drug: Riboflavin<br>* 01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes<br>* Other names: Vitamin B2;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in keratometry |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| best spectacle-corrected visual acuity |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
keratoconus, ectasia, cross-linking, riboflavin, UVA light, cornea
Effects of Anke Malz on Women During Lactation

Study Overview
=================
Brief Summary
-----------------
Human milk is the most optimal food to provide all infants' needs before eating solid food. However, underproduction of milk is a common and concerned problem for breastfeeding women. In this case, proper milk-making foods reveal their importance on lactation. In many European countries, ancient wisdom clams that non-alcoholic malt beverage could facilitate the secretion of breast milk. This study estimates the effects of non-alcoholic malt product during first three months of lactation.

Official Title
-----------------
Effects of Anke Malz on Women During Lactation

Conditions
-----------------
Non-alcoholic Malt Product in Lactation

Intervention / Treatment
-----------------
* Dietary Supplement: Anke Malz


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single fetal pregnancy Full time birth Exclusion Criteria: Any complication during pregnancy Smokers Alcohol or drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control<br>subjects drunk no Anke Malz product. | |
| Experimental: intervention one<br>subjects drunk one can Anke Malz product. | Dietary Supplement: Anke Malz<br>* non-alcoholic malt drink<br>|
| Experimental: intervention two<br>subjects drunk two cans Anke Malz product. | Dietary Supplement: Anke Malz<br>* non-alcoholic malt drink<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The concentration of prolactin on lactational women |  | three months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean breast-feeding time |  | three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lactation, human milk, maltz, antioxidant
Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Study Overview
=================
Brief Summary
-----------------
Subjects enrolled in the SP615, SP756, or SP774 open-label extension (OLE) trials receiving oral SPM 927 for at least 8 weeks and a stable dose of up to 3 antiepileptic medications may participate in a research trial at approximately 30 locations. Trial objectives include investigating whether iv SPM 927 is safe and well tolerated when given twice daily for a short period of time and identifying the appropriate infusion rate(s). Subjects will receive SPM 927 as a 30-, 15- or 10- minute infusions twice daily for 2 - 5 days based on notification by the research doctor and subject choice. Subjects will remain on the same stable dose as received in the OLE trial. Trial procedures will include medical history update, physical/ neurological exams, ECGs, blood /urine sample collections and seizure diary completion. Subjects completing the trial will return to the OLE trial to resume dosing with oral SPM 927.

Official Title
-----------------
A Multicenter, Open-label Trial to Investigate the Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization.

Conditions
-----------------
Epilepsies, Partial

Intervention / Treatment
-----------------
* Drug: SPM 927


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Partial seizures with or without secondary generalization. Exclusion Criteria: Subject has previously received iv lacosamide. Subject meets the withdrawal criteria for the open-label extension trial.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SPM 927|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the safety and tolerability of lacosamide when given as iv infusions in subjects who are receiving oral lacosamide in addition to up to 3 concomitant AEDs for partial seizures. The primary variables are adverse events |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seizure counts, trough and measured maximum concentration for lacosamide as well as the O-desmethyl-metabolite. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
partial seizures with or without secondary generalization
Improved HRV, Inflammation Markers and Endothelial Function After TAVI

Study Overview
=================
Brief Summary
-----------------
Severe aortic valve stenosis is known to affect heart haemodynamics, endothelial function and body inflammation markers. Our aim is to investigate the weather transcatheter aortic valve implantation in patients with severe aortic stenosis affects heart rate variability, inflammation markers and endothelial function.

Official Title
-----------------
Improved Heart Rate Variability, Inflammation Markers and Endothelial Function After Transcatheter Aortic Valve Implantation

Conditions
-----------------
Severe Aortic Stenosis, TAVI

Intervention / Treatment
-----------------
* Diagnostic Test: Flow mediated vasodilatation
* Diagnostic Test: High resolution ECG
* Diagnostic Test: Blood withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TAVI Exclusion Criteria: stage V chronic kidney disease active malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TAVI group<br>Consecutive patients undergoing TAVI | Diagnostic Test: Flow mediated vasodilatation<br>* Measurement of brachial artery diameter change before and after limb ischaemia.<br>Diagnostic Test: High resolution ECG<br>* Measurement HRV using high resolution ECG<br>Diagnostic Test: Blood withdrawal<br>* Measurement of endothelial inflammation markers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of heart rate variability | Change of heart rate variability (HRV) estimated with digital high resolution ECG recording | 3 to 6 months after TAVI | 
| Change of laboratory value of endothelial inflammation markers | Laboratory determined numerical changes in endothelial inflammation markers | 3 to 6 months after TAVI | 
| Change of flow-mediated filatation (FMD) of the brachial artery | % flow-mediated dilatation | 3 to 6 months after TAVI |
Injury Occurrence in Hip-hop Dance

Study Overview
=================
Brief Summary
-----------------
The study will investigate the effect of structural training program and body composition on injury occurrence in hip-hop dance. Assuming that training program can significantly lower the number of injuries (experimental group will have less injuries during and at the end of the trial) and that body fat percentage negatively effects injury occurrence (dancers with higher body fat percentage will be more often injured).

Official Title
-----------------
The Effect of Structured Training Program and Body Composition on Injury Occurrence in Hip-hop Dance

Conditions
-----------------
Sports Injury, Body Composition

Intervention / Treatment
-----------------
* Other: Structural training program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hip-hop dancer (active) Exclusion Criteria: injured

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental group<br>Performing a structural training program twice a week, 30 minutes each. | Other: Structural training program<br>* 15-week experimental structural training protocol<br>|
| No Intervention: Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of injuries |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hip-hop dance, injuries, body fat
Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to establish a platform of detecting and sorting circulating tumor stem cells from peripheral blood in HCC patients; to investigate the relationship between circulating tumor stem cells and their effects on postoperative recurrence and metastasis, in order to provide a new therapeutic target for hepatocellular carcinoma treatment.

Official Title
-----------------
A Prospective Randomized Trial on the Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology

Conditions
-----------------
Cancer Stem Cells, Postoperative Recurrence and Metastasis, Hepatocellular Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients > 18 years and <=70 years of age; No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Patients who can understand this trial and have signed information consent Exclusion Criteria: Reject to attend； Impossible to come to our hospital for physical examination regularly; Patients with other diseases which may affect the treatment mentioned

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy volunteers<br>matched group | |
| hepatitis cirrhosis<br>negative group | |
| hepatocellular carcinoma<br>patients with primary HCC | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the overall survival rate of each group |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer stem cells
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Study Overview
=================
Brief Summary
-----------------
This trial is looking at whether the LEO 90100 foam causes irritation of the skin in healthy Japanese male adults without psoriasis. A single application of LEO 90100 foam and its vehicle will each be made to 2 body sites in 20 subjects.

Official Title
-----------------
Skin Irritation Trial of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Drug: LEO 90100 foam
* Drug: Vehicle of LEO 90100 foam


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Signed informed consent has been obtained. Healthy Japanese male subjects. Aged 20 to 40 years inclusive. Key Exclusion Criteria: Body Mass Index outside the range 18-25 kg/m² Use of any medication (systemic or topical) within 2 weeks of Day 1.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LEO 90100 foam<br>Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g | Drug: LEO 90100 foam<br>* Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back<br>|
| Placebo Comparator: Vehicle foam<br>Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner. Foam vehicle does not contain active ingredients | Drug: Vehicle of LEO 90100 foam<br>* Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin irritation | Skin irritation measured as skin irritation index (summation of clinical scores [ranging from no reaction to blisters] from 49 hrs to 72 hrs after aplication) divided by total number of skin irritation assessments | Up to Day 4 | 
| Photo irritation | Positive ratios calculated from the photo irritation scores | Up to Day 4 |